Logo image of RPRX

ROYALTY PHARMA PLC- CL A (RPRX) Stock Price, Quote, News and Overview

NASDAQ:RPRX - Nasdaq - GB00BMVP7Y09 - Common Stock - Currency: USD

36.19  +0.31 (+0.86%)

After market: 36.4771 +0.29 (+0.79%)

RPRX Quote, Performance and Key Statistics

ROYALTY PHARMA PLC- CL A

NASDAQ:RPRX (7/2/2025, 8:00:02 PM)

After market: 36.4771 +0.29 (+0.79%)

36.19

+0.31 (+0.86%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High36.33
52 Week Low24.05
Market Cap20.35B
Shares562.24M
Float382.27M
Yearly Dividend0.63
Dividend Yield2.5%
PE9.6
Fwd PE7.04
Earnings (Next)08-06 2025-08-06/bmo
IPO06-16 2020-06-16


RPRX short term performance overview.The bars show the price performance of RPRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40

RPRX long term performance overview.The bars show the price performance of RPRX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 30 40

The current stock price of RPRX is 36.19 USD. In the past month the price increased by 8.71%. In the past year, price increased by 40.98%.

ROYALTY PHARMA PLC- CL A / RPRX Daily stock chart

RPRX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 56.63 738.55B
JNJ JOHNSON & JOHNSON 15.48 374.29B
NVO NOVO-NORDISK A/S-SPONS ADR 18.87 310.24B
NVS NOVARTIS AG-SPONSORED ADR 14.9 244.54B
AZN ASTRAZENECA PLC-SPONS ADR 16.17 220.53B
MRK MERCK & CO. INC. 10.58 206.88B
PFE PFIZER INC 7.89 143.95B
SNY SANOFI-ADR 10.77 120.00B
BMY BRISTOL-MYERS SQUIBB CO 6.49 96.93B
GSK GSK PLC-SPON ADR 8.56 78.04B
ZTS ZOETIS INC 26.43 70.82B
TAK TAKEDA PHARMACEUTIC-SP ADR 64.25 48.17B

About RPRX

Company Profile

RPRX logo image Royalty Pharma Plc engages in the provision of drug development services. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2020-06-16. The firm collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The company funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates.

Company Info

ROYALTY PHARMA PLC- CL A

110 East 59th Street

New York City NEW YORK 10022 US

CEO: Pablo Legorreta

Employees: 99

RPRX Company Website

RPRX Investor Relations

Phone: 12128830200

ROYALTY PHARMA PLC- CL A / RPRX FAQ

What is the stock price of ROYALTY PHARMA PLC- CL A today?

The current stock price of RPRX is 36.19 USD. The price increased by 0.86% in the last trading session.


What is the ticker symbol for ROYALTY PHARMA PLC- CL A stock?

The exchange symbol of ROYALTY PHARMA PLC- CL A is RPRX and it is listed on the Nasdaq exchange.


On which exchange is RPRX stock listed?

RPRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ROYALTY PHARMA PLC- CL A stock?

13 analysts have analysed RPRX and the average price target is 41.76 USD. This implies a price increase of 15.4% is expected in the next year compared to the current price of 36.19. Check the ROYALTY PHARMA PLC- CL A stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ROYALTY PHARMA PLC- CL A worth?

ROYALTY PHARMA PLC- CL A (RPRX) has a market capitalization of 20.35B USD. This makes RPRX a Large Cap stock.


How many employees does ROYALTY PHARMA PLC- CL A have?

ROYALTY PHARMA PLC- CL A (RPRX) currently has 99 employees.


What are the support and resistance levels for ROYALTY PHARMA PLC- CL A (RPRX) stock?

ROYALTY PHARMA PLC- CL A (RPRX) has a support level at 34.48. Check the full technical report for a detailed analysis of RPRX support and resistance levels.


Is ROYALTY PHARMA PLC- CL A (RPRX) expected to grow?

The Revenue of ROYALTY PHARMA PLC- CL A (RPRX) is expected to grow by 9.21% in the next year. Check the estimates tab for more information on the RPRX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ROYALTY PHARMA PLC- CL A (RPRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ROYALTY PHARMA PLC- CL A (RPRX) stock pay dividends?

ROYALTY PHARMA PLC- CL A (RPRX) has a dividend yield of 2.5%. The yearly dividend amount is currently 0.63. Check the full fundamental report for a detailed analysis of RPRX dividend history, reliability and sustainability.


When does ROYALTY PHARMA PLC- CL A (RPRX) report earnings?

ROYALTY PHARMA PLC- CL A (RPRX) will report earnings on 2025-08-06, before the market open.


What is the Price/Earnings (PE) ratio of ROYALTY PHARMA PLC- CL A (RPRX)?

The PE ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.6. This is based on the reported non-GAAP earnings per share of 3.77 and the current share price of 36.19 USD. Check the full fundamental report for a full analysis of the valuation metrics for RPRX.


What is the Short Interest ratio of ROYALTY PHARMA PLC- CL A (RPRX) stock?

The outstanding short interest for ROYALTY PHARMA PLC- CL A (RPRX) is 7.59% of its float. Check the ownership tab for more information on the RPRX short interest.


RPRX Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to RPRX. When comparing the yearly performance of all stocks, RPRX is one of the better performing stocks in the market, outperforming 82.18% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

RPRX Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to RPRX. RPRX has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RPRX Financial Highlights

Over the last trailing twelve months RPRX reported a non-GAAP Earnings per Share(EPS) of 3.77. The EPS increased by 0.27% compared to the year before.


Industry RankSector Rank
PM (TTM) 48.26%
ROA 6.2%
ROE 16.33%
Debt/Equity 0.99
Chartmill High Growth Momentum
EPS Q2Q%-33.67%
Sales Q2Q%47.71%
EPS 1Y (TTM)0.27%
Revenue 1Y (TTM)1.13%

RPRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to RPRX. The Buy consensus is the average rating of analysts ratings from 13 analysts.

For the next year, analysts expect an EPS growth of 9.34% and a revenue growth 9.21% for RPRX


Ownership
Inst Owners78.78%
Ins Owners1.82%
Short Float %7.59%
Short Ratio5.91
Analysts
Analysts81.54
Price Target41.76 (15.39%)
EPS Next Y9.34%
Revenue Next Year9.21%